CoronaVac inoculation has been given to tens of thousands in China under emergency use program and has been ordered by Thailand, Singapore, Hong Kong and Brazil

Limited publishing of clinical trial data by domestic Covid-19 vaccine developers suggests efficacy results vary widely, threatening to undermine public trust, says director of institute co-founded by the Gates Foundation

China cuts red tape to beef up its interbank bond market. The country’s Sinopharm says its Covid-19 vaccine is 79% effective

State-backed CNBG reports 79.34% effectiveness of inactivated-virus shot and seeks regulatory clearance for general distribution

The data was from trials that included 31,000 volunteers in the UAE, which found the vaccine was highly effective in preventing moderate and severe cases

Program expansion also includes general public in two cities and widespread emergency use, even without trial results on safety and effectiveness

China's farmers sell less wheat and expect prices to rise. Plus, a bottled water giant gets a spectacular debut on the Hong Kong stock exchange

Under emergency program, government permits expanding use of inoculations developed by China National Biotec Group, Sinovac and CanSino that are still in clinical trials

State-owned China National Biotec Group to work with Abu Dhabi’s AI company G42 in Middle Eastern coronavirus hot spot

Investors flock to Sinopharm and two units as human trials indicate experimental Covid-19 inoculation is safe and elicits antibodies